EA201992886A1 - Активируемые антитела против pdl1 и способы их применения - Google Patents
Активируемые антитела против pdl1 и способы их примененияInfo
- Publication number
- EA201992886A1 EA201992886A1 EA201992886A EA201992886A EA201992886A1 EA 201992886 A1 EA201992886 A1 EA 201992886A1 EA 201992886 A EA201992886 A EA 201992886A EA 201992886 A EA201992886 A EA 201992886A EA 201992886 A1 EA201992886 A1 EA 201992886A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies against
- ways
- activated antibodies
- application
- pdl1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение в целом относится к активируемым антителам, которые специфично связываются с PDL1, и к способам получения и применения таких активируемых антител против PDL1 по различным терапевтическим, диагностическим и профилактическим показаниям.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862657567P | 2018-04-13 | 2018-04-13 | |
PCT/US2018/035508 WO2018222949A1 (en) | 2017-06-01 | 2018-05-31 | Activatable anti-pdl1 antibodies, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992886A1 true EA201992886A1 (ru) | 2020-05-12 |
Family
ID=70847628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992886A EA201992886A1 (ru) | 2018-04-13 | 2018-05-31 | Активируемые антитела против pdl1 и способы их применения |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201992886A1 (ru) |
-
2018
- 2018-05-31 EA EA201992886A patent/EA201992886A1/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792413A1 (ru) | Антитела против cd71, активируемые антитела против cd71 и способы их применения | |
EA201792414A1 (ru) | Антитела против cd166, активируемые антитела против cd166 и способы их применения | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
EA201991720A1 (ru) | Антитела к альфа-синуклеину и их применения | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
EA201691541A1 (ru) | Новые анти-baff антитела | |
EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
EA201892716A1 (ru) | Антитела к фактору свертывания xi | |
EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA201891299A1 (ru) | Терапевтические антитела к cd9 | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
EA201992883A1 (ru) | АНТИТЕЛА К TrkB |